Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

701P - Concordance of different immunohistochemical assays in MET protein overexpression detection in lung adenocarcinoma

Date

07 Dec 2024

Session

Poster Display session

Presenters

Li Liu

Citation

Annals of Oncology (2024) 35 (suppl_4): S1632-S1678. 10.1016/annonc/annonc1698

Authors

W. Rao, L. Liu, L. Guo, L. Gao, J. Ying

Author affiliations

  • Department Of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021 - Beijing/CN

Resources

This content is available to ESMO members and event participants.

Abstract 701P

Background

Overexpression of the mesenchymal epithelial transition factor (MET) protein represents a potential therapeutic target in lung cancer, underscoring the importance of accurate detection for effective treatment. Various assays are utilized for MET immunohistochemistry (IHC) testing in clinical research and practice, but the lack of research on their detection performance significantly limits the availability and standardization of testing. This study is the first to evaluate the concordance of various MET IHC assays in lung adenocarcinoma (LUAD).

Methods

One hundred formalin-fixed and paraffin-embedded tumour tissues (50 surgical and 50 biopsy) from Chinese LUAD patients between 2022∼2024 were enrolled. Retrospective IHC detection was performed using four MET antibodies—SP44, LBP4, D1C2, MXR039 with corresponding visualization and platforms. Slides were independently evaluated by two experienced pathologists according to Clinical Score, with strong staining in ≥50% of tumour cells defined as positive. Overall consistency, sensitivity and specificity were assessed with SP44 as a reference.

Results

Twenty-four samples were verified as positive using SP44. Using SP44 as a reference, the overall consistency of LBP4, D1C2, and MXR039 staining was 98% (98/100), 95.00% (95/100), and 95.00% (95/100), while sensitivity rates were 100.00% (24/24), 83.33% (20/24), 95.83% (23/24) and specificity rates were 97.37% (74/76), 98.68% (75/76), 94.74% (72/76), respectively.

Conclusions

Our results show good concordance in four assays, which provides more options for clinical MET IHC detection in LUAD. Subtle variations in staining performance of different assays and subjective nature of pathological evaluation may contribute to the discrepancies in staining evaluation results, which highly prompts labs to establish a standard operating procedure and enhance interpretation training for each assay.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.